Literature DB >> 8332613

Differential effects of scopolamine and mecamylamine on working and reference memory in the rat.

P M Moran1.   

Abstract

The effects of the muscarinic antagonist scopolamine (0.1-0.6 mg/kg, IP) and the nicotinic antagonist mecamylamine (1-10 mg/kg) were compared in T-maze alternation and discrimination tasks in the rat. Scopolamine dose dependently disrupted performance on the alternation task and potentiated the increase in errors made in controls when the delay between forced and choice runs was increased from 0 to 30 s. Mecamylamine disrupted performance at the 10-mg/kg dose only and dose dependently inhibited the increase in errors made in controls when the delay between forced and choice runs was increased to 30 s. In simple T-maze discrimination, only the 0.6-mg/kg dose of scopolamine disrupted performance of the task, while mecamylamine at both 5 and 10 mg/kg disrupted task performance. These results confirm that working memory tasks are more sensitive to central muscarinic blockade than reference memory tasks. They also demonstrate that in delay conditions working memory performance is enhanced following central nicotinic blockade while reference memory performance is disrupted. This suggests that centrally active muscarinic and nicotinic antagonists have dissociable effects on memory processes in the rat.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8332613     DOI: 10.1016/0091-3057(93)90502-k

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  15 in total

Review 1.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 2.  Animal models in the drug discovery pipeline for Alzheimer's disease.

Authors:  Debby Van Dam; Peter Paul De Deyn
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 3.  Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics.

Authors:  P A Newhouse; A Potter; E D Levin
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

4.  Cholinergic modulation of a decrement in social investigation following repeated contacts between mice.

Authors:  J T Winslow; F Camacho
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

5.  Nicotinic and muscarinic receptors in the rat prefrontal cortex: differential roles in working memory, response selection and effortful processing.

Authors:  S Granon; B Poucet; C Thinus-Blanc; J P Changeux; C Vidal
Journal:  Psychopharmacology (Berl)       Date:  1995-05       Impact factor: 4.530

6.  Chronic stress induces impairment of spatial working memory because of prefrontal dopaminergic dysfunction.

Authors:  K Mizoguchi; M Yuzurihara; A Ishige; H Sasaki; D H Chui; T Tabira
Journal:  J Neurosci       Date:  2000-02-15       Impact factor: 6.167

7.  Inhibitory learning is modulated by nicotinic acetylcholine receptors.

Authors:  Heidi C Meyer; Rachel B Putney; David J Bucci
Journal:  Neuropharmacology       Date:  2015-02       Impact factor: 5.250

8.  Mice lacking dopamine D2 and D3 receptors have spatial working memory deficits.

Authors:  Sara B Glickstein; Patrick R Hof; Claudia Schmauss
Journal:  J Neurosci       Date:  2002-07-01       Impact factor: 6.167

9.  The ambivalent behaviour "stretched approach posture" in the rat as a paradigm to characterize anxiolytic drugs.

Authors:  H E Molewijk; A M van der Poel; B Olivier
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

10.  Involvement of the sigma1 (sigma1) receptor in the anti-amnesic, but not antidepressant-like, effects of the aminotetrahydrofuran derivative ANAVEX1-41.

Authors:  J Espallergues; P Lapalud; A Christopoulos; V A Avlani; P M Sexton; A Vamvakides; T Maurice
Journal:  Br J Pharmacol       Date:  2007-08-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.